Bailey Jason, Piert Morand
Department of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Department of Radiology, Division of Nuclear Medicine, University of Michigan Health System, University Hospital B1G505C, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-0028, USA.
Curr Urol Rep. 2017 Sep 9;18(11):84. doi: 10.1007/s11934-017-0736-1.
Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC (Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer.
Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL). However, the majority of published work lacks rigorous verification of imaging results. Ga-PSMA offers significant promise for both, primary disease and biochemically recurrent prostate cancer. The evidence base to support Ga-PSMA is however still underdeveloped, and more rigorous studies substantiating efficacy are needed.
最近引入的镓 - 68标记的PSMA配体，如HBED - CC（镓 - PSMA），已显示出有望满足前列腺癌未得到满足的诊断需求。
与标准成像方法相比，镓 - PSMA已证明对前列腺癌的检测率和特异性有所提高。在原发性疾病的情况下，镓 - PSMA似乎优先识别与治疗相关的中高危前列腺癌。越来越多的证据表明，在生化复发时，尤其是在较低的前列腺特异性抗原（PSA）水平（<1 ng/mL）下，镓 - PSMA正电子发射断层扫描（PET）在疾病部位定位方面优于包括基于胆碱的放射性示踪剂在内的其他传统成像方法。然而，大多数已发表的研究缺乏对成像结果的严格验证。镓 - PSMA对原发性疾病和生化复发的前列腺癌都具有重大前景。然而，支持镓 - PSMA的证据基础仍不完善，需要更严格的研究来证实其疗效。
